From: A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice
Added dose of afatinib (ng)
Tumor-to-background ratio
0
2.3 ± 0.4*
100
1.1 ± 0.4
300
1.0 ± 0.3
1,000
0.9 ± 0.2
3,000
0.9 ± 0.3